Sanofi (FRA:SNW)

Germany flag Germany · Delayed Price · Currency is EUR
79.32
-0.09 (-0.11%)
Last updated: Sep 24, 2025, 5:35 PM CET
-0.11%
Market Cap96.74B
Revenue (ttm)45.74B
Net Income (ttm)9.13B
Shares Outn/a
EPS (ttm)7.36
PE Ratio10.60
Forward PE9.76
Dividend3.92 (4.89%)
Ex-Dividend DateMay 12, 2025
Volume3,481
Average Volume2,183
Open79.38
Previous Close79.41
Day's Range79.27 - 79.92
52-Week Range76.92 - 110.02
Betan/a
RSI40.13
Earnings DateOct 24, 2025

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]

Industry Pharmaceutical Preparations
Founded 1994
Employees 82,878
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol SNW
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial Statements

News

Sanofi Commits $625 Mln To Expand Venture Fund

(RTTNews) - Sanofi Winthrop Industrie SA, Sanofi SA (SAN.PA, SNY, SNYNF), a French pharmaceutical and healthcare company, on Wednesday said it has made an additional $625 million multi-year capital co...

21 hours ago - Nasdaq

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation

Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare di...

21 hours ago - Wallstreet:Online

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation

Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare di...

21 hours ago - GlobeNewsWire

Press release: Availability of the Q3 2025 Aide mémoire

Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Third q...

21 hours ago - Wallstreet:Online

Press release: Availability of the Q3 2025 Aide mémoire

Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Third q...

21 hours ago - GlobeNewsWire

Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sanofi (NEOE:SAN:CA) Bank of America Global Healthcare Conference 2025 September 23, 2025 4:50 AM EDTCompany ParticipantsPaul Hudson - CEO &...

1 day ago - Seeking Alpha

FDA Grants Fast Track Status To Sanofi's Gene Therapy For Non-Congenital DM1

(RTTNews) - The U.S. Food and Drug Administration has granted Fast Track designation to SAR446268, Sanofi's (SNY,SNYNF,SAN.PA) investigational one-time AAV gene therapy targeting non-congenital forms ...

1 day ago - Nasdaq

Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1

Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK ex...

1 day ago - Wallstreet:Online

Press Release: Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1

Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK ex...

1 day ago - GlobeNewsWire

Press Release: Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1

Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK ex...

1 day ago - Benzinga

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision

Sanofi's tolebrutinib review for non-relapsing ... Full story available on Benzinga.com

2 days ago - Benzinga

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU

Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.

2 days ago - Nasdaq

Sanofi (SNY) Advances with Dupixent for Skin Condition in EU

Sanofi (SNY) Advances with Dupixent for Skin Condition in EU

2 days ago - GuruFocus

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recomm...

2 days ago - Nasdaq

Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis

Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three...

2 days ago - GlobeNewsWire

Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig...

2 days ago - Benzinga

Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig...

2 days ago - GlobeNewsWire

Irelands pharma sector is world class, but why dont we have a Novo Nordisk to take our success to the next level?

Denmark has Novo Nordisk, France has Sanofi, Switzerland boasts both Roche and Novartis, while Germany has Bayer. Its a somewhat troubled relationship, but Britain has AstraZeneca.

6 days ago - Independent Ireland

Sanofi's Brivekimig Shows Efficacy In Biologic-Naïve HS Patients In Phase 2a Study

(RTTNews) - Sanofi (SNY) announced promising new data from its HS-OBTAIN phase 2a study, highlighting the efficacy of brivekimig in treating biologic-naïve patients with moderate-to-severe hidradeniti...

7 days ago - Nasdaq

Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study

EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary e...

7 days ago - Benzinga

Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study

EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary e...

7 days ago - GlobeNewsWire

How the UK fell out with big pharma

The U.K. is in the midst of a falling out with big pharma over drug pricing. Merck has walked away from a 1 billion facility in London and pulled its research activities altogether. Now Eli Lilly, San...

9 days ago - CNBC

Britain is ‘a terrible place’ to sell medicines, says drug firm executive

Sanofi’s market access chief urges ministers to come up with a roadmap to raise spending on new treatments Business live – latest updates A senior pharmaceuticals executive has called on the governmen...

12 days ago - The Guardian

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t...

13 days ago - Benzinga

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t...

13 days ago - GlobeNewsWire